<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="recognize">
            <roleset id="recognize.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing being identified&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>A monoclonal antibody also binds to these 7-2-7 sites but, unlike NarP, also recognizes the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A monoclonal antibody also bound to these 7-2-7 sites but, unlike NarP, also recognized the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A monoclonal antibody are able to recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>A monoclonal antibody can recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>A monoclonal antibody has also bound to these 7-2-7 sites but, unlike NarP, has also recognized the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A monoclonal antibody have recognized the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>A monoclonal antibody recognize specifically the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>A monoclonal antibody recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>A monoclonal antibody recognized specifically the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>A monoclonal antibody recognized the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>A monoclonal antibody will binds to these 7-2-7 sites but, unlike NarP, will also recognize the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>A monoclonal antibody will recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Anti-64kD human autoantigen D1 antibodies also binds to these 7-2-7 sites but, unlike NarP, also recognizes a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Anti-64kD human autoantigen D1 antibodies also bound to these 7-2-7 sites but, unlike NarP, also recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Anti-64kD human autoantigen D1 antibodies are able to recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Anti-64kD human autoantigen D1 antibodies can recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Anti-64kD human autoantigen D1 antibodies has also bound to these 7-2-7 sites but, unlike NarP, has also recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Anti-64kD human autoantigen D1 antibodies have recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Anti-64kD human autoantigen D1 antibodies recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Anti-64kD human autoantigen D1 antibodies recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Anti-64kD human autoantigen D1 antibodies recognizing a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Anti-64kD human autoantigen D1 antibodies which has recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Anti-64kD human autoantigen D1 antibodies which recognizes a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Anti-64kD human autoantigen D1 antibodies will binds to these 7-2-7 sites but, unlike NarP, will also recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Anti-64kD human autoantigen D1 antibodies will recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Blots were probed with A monoclonal antibody recognizing the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Blots were probed with A monoclonal antibody that can recognize the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Blots were probed with A monoclonal antibody that recognized the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Blots were probed with A monoclonal antibody that recognizes the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Blots were probed with A monoclonal antibody that recognizes the the STAT1 N-terminus, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Blots were probed with A monoclonal antibody that recognizes the the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Blots were probed with Anti-64kD human autoantigen D1 antibodies recognizing a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Blots were probed with Anti-64kD human autoantigen D1 antibodies that can recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Blots were probed with Anti-64kD human autoantigen D1 antibodies that recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Blots were probed with Anti-64kD human autoantigen D1 antibodies that recognizes a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Blots were probed with Anti-64kD human autoantigen D1 antibodies that recognizes the a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Blots were probed with Anti-64kD human autoantigen D1 antibodies that recognizes the a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Blots were probed with Most regulators belonging to the AraC/XylS family recognizing multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Blots were probed with Most regulators belonging to the AraC/XylS family that can recognize multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Blots were probed with Most regulators belonging to the AraC/XylS family that recognized multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Blots were probed with Most regulators belonging to the AraC/XylS family that recognizes multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Blots were probed with Most regulators belonging to the AraC/XylS family that recognizes the multiple binding sites, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Blots were probed with Most regulators belonging to the AraC/XylS family that recognizes the multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Blots were probed with The NarL protein recognizing heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Blots were probed with The NarL protein that can recognize heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Blots were probed with The NarL protein that recognized heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Blots were probed with The NarL protein that recognizes heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Blots were probed with The NarL protein that recognizes the heptamers in other arrangements, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Blots were probed with The NarL protein that recognizes the heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Blots were probed with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognizing sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Blots were probed with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) that can recognize sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Blots were probed with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) that recognized sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Blots were probed with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) that recognizes sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Blots were probed with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) that recognizes the sequence(YPYDVPDYA) at a 1:500 dilution, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Blots were probed with a monoclonal antibody recognizing the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Blots were probed with a monoclonal antibody that can recognize the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Blots were probed with a monoclonal antibody that recognized the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Blots were probed with a monoclonal antibody that recognizes the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Blots were probed with a monoclonal antibody that recognizes the the STAT1 N-terminus, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Blots were probed with a monoclonal antibody that recognizes the the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Blots were probed with affinity-purified polyclonal anti-LMP-1 antiserum that recognizes the epitopes in the C-terminus of LMP-1 at a 1:200 dilution, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Blots were probed with affinity-purified polyclonal anti-LMP-1 antiserum that recognizes the epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Blots were probed with anti-Stat3 pAb recognizing The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Blots were probed with anti-Stat3 pAb that can recognize The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Blots were probed with anti-Stat3 pAb that recognized The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Blots were probed with anti-Stat3 pAb that recognizes The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Blots were probed with anti-Stat3 pAb that recognizes the The lower form of Stat3, Stat3Beta, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Blots were probed with anti-Stat3 pAb that recognizes the The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Blots were probed with four different specific antibodies recognizing the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Blots were probed with four different specific antibodies that can recognize the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Blots were probed with four different specific antibodies that recognized the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Blots were probed with four different specific antibodies that recognizes the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Blots were probed with four different specific antibodies that recognizes the the different nonmuscle myosin heavy chain isoforms (A and B), or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Blots were probed with four different specific antibodies that recognizes the the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Blots were probed with rabbit polyclonal anti-CD40 antiserum recognizing C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Blots were probed with rabbit polyclonal anti-CD40 antiserum that can recognize C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Blots were probed with rabbit polyclonal anti-CD40 antiserum that recognized C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Blots were probed with rabbit polyclonal anti-CD40 antiserum that recognizes C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Blots were probed with rabbit polyclonal anti-CD40 antiserum that recognizes the C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Blots were probed with the cAMP-CRP activator complex recognizing two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Blots were probed with the cAMP-CRP activator complex that can recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Blots were probed with the cAMP-CRP activator complex that recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Blots were probed with the cAMP-CRP activator complex that recognizes the two sites in tsx-p2, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Blots were probed with the cAMP-CRP activator complex that recognizes the two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Blots were probed with the cAMP-CRP activator complex that recognizes two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Blots were probed with the proteins recognizing short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Blots were probed with the proteins that can recognize short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Blots were probed with the proteins that recognized short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Blots were probed with the proteins that recognizes short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Blots were probed with the proteins that recognizes the short motifs within the protected region, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Blots were probed with the proteins that recognizes the short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Blots were probed with this antibody in PKR+/+MEFs recognizing The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Blots were probed with this antibody in PKR+/+MEFs that can recognize The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Blots were probed with this antibody in PKR+/+MEFs that recognized The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Blots were probed with this antibody in PKR+/+MEFs that recognizes The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Blots were probed with this antibody in PKR+/+MEFs that recognizes the The two forms of Stat3 (Stat3fm and Stat3sm), or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Blots were probed with this antibody in PKR+/+MEFs that recognizes the The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>C-terminus of CD40 at a 1:500 dilution are recognized by rabbit polyclonal anti-CD40 antiserum.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>C-terminus of CD40 at a 1:500 dilution recognized by rabbit polyclonal anti-CD40 antiserum are indicated.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>C-terminus of CD40 at a 1:500 dilution that are recognized by rabbit polyclonal anti-CD40 antiserum are indicated.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>C-terminus of CD40 at a 1:500 dilution that have been recognized by rabbit polyclonal anti-CD40 antiserum are indicated.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>C-terminus of CD40 at a 1:500 dilution that were recognized by rabbit polyclonal anti-CD40 antiserum are indicated.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>C-terminus of CD40 at a 1:500 dilution that will be recognized by rabbit polyclonal anti-CD40 antiserum are indicated.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>C-terminus of CD40 at a 1:500 dilution were recognized by rabbit polyclonal anti-CD40 antiserum.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>C-terminus of CD40 at a 1:500 dilution which can be recognized by rabbit polyclonal anti-CD40 antiserum are indicated.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>C-terminus of CD40 at a 1:500 dilution which were recognized by rabbit polyclonal anti-CD40 antiserum are indicated.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>C-terminus of CD40 at a 1:500 dilution, cannot be recognized in the immunoprecipitaiton with rabbit polyclonal anti-CD40 antiserum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>C-terminus of CD40 at a 1:500 dilution, could not be recognized in the immunoprecipitaiton with rabbit polyclonal anti-CD40 antiserum as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>C-terminus of CD40 at a 1:500 dilution, has not been recognized in the immunoprecipitaiton with rabbit polyclonal anti-CD40 antiserum as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>C-terminus of CD40 at a 1:500 dilution, is not recognized in the immunoprecipitaiton with rabbit polyclonal anti-CD40 antiserum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>C-terminus of CD40 at a 1:500 dilution, was not recognized in the immunoprecipitaiton with rabbit polyclonal anti-CD40 antiserum as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>C-terminus of CD40 at a 1:500 dilution, will not be recognized in the immunoprecipitaiton with rabbit polyclonal anti-CD40 antiserum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that A monoclonal antibody are able to recognize the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that A monoclonal antibody can recognize the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that A monoclonal antibody has recognized the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that A monoclonal antibody recognize the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that A monoclonal antibody recognized the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Anti-64kD human autoantigen D1 antibodies are able to recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Anti-64kD human autoantigen D1 antibodies can recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Anti-64kD human autoantigen D1 antibodies has recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Anti-64kD human autoantigen D1 antibodies recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Anti-64kD human autoantigen D1 antibodies recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Most regulators belonging to the AraC/XylS family are able to recognize multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Most regulators belonging to the AraC/XylS family can recognize multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Most regulators belonging to the AraC/XylS family has recognized multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Most regulators belonging to the AraC/XylS family recognize multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Most regulators belonging to the AraC/XylS family recognized multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that The NarL protein are able to recognize heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that The NarL protein can recognize heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that The NarL protein has recognized heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that The NarL protein recognize heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that The NarL protein recognized heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) are able to recognize sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) can recognize sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) has recognized sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognize sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognized sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody are able to recognize the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody can recognize the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody has recognized the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody recognize the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody recognized the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that affinity-purified polyclonal anti-LMP-1 antiserum are able to recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that affinity-purified polyclonal anti-LMP-1 antiserum can recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that affinity-purified polyclonal anti-LMP-1 antiserum has recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that affinity-purified polyclonal anti-LMP-1 antiserum recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that affinity-purified polyclonal anti-LMP-1 antiserum recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb are able to recognize The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb can recognize The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb has recognized The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb recognize The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb recognized The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that four different specific antibodies are able to recognize the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that four different specific antibodies can recognize the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that four different specific antibodies has recognized the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that four different specific antibodies recognize the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that four different specific antibodies recognized the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that rabbit polyclonal anti-CD40 antiserum are able to recognize C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that rabbit polyclonal anti-CD40 antiserum can recognize C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that rabbit polyclonal anti-CD40 antiserum has recognized C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that rabbit polyclonal anti-CD40 antiserum recognize C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that rabbit polyclonal anti-CD40 antiserum recognized C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex can recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex has recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that this antibody in PKR+/+MEFs are able to recognize The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that this antibody in PKR+/+MEFs can recognize The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that this antibody in PKR+/+MEFs has recognized The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that this antibody in PKR+/+MEFs recognize The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that this antibody in PKR+/+MEFs recognized The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where C-terminus of CD40 at a 1:500 dilution are recognized by rabbit polyclonal anti-CD40 antiserum.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where C-terminus of CD40 at a 1:500 dilution were recognized by rabbit polyclonal anti-CD40 antiserum.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where The lower form of Stat3, Stat3Beta are recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where The lower form of Stat3, Stat3Beta were recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where The two forms of Stat3 (Stat3fm and Stat3sm) are recognized by this antibody in PKR+/+MEFs.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where The two forms of Stat3 (Stat3fm and Stat3sm) were recognized by this antibody in PKR+/+MEFs.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle are recognized by Anti-64kD human autoantigen D1 antibodies.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle were recognized by Anti-64kD human autoantigen D1 antibodies.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where epitopes in the C-terminus of LMP-1 at a 1:200 dilution are recognized by affinity-purified polyclonal anti-LMP-1 antiserum.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where epitopes in the C-terminus of LMP-1 at a 1:200 dilution were recognized by affinity-purified polyclonal anti-LMP-1 antiserum.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where heptamers in other arrangements are recognized by The NarL protein.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where heptamers in other arrangements were recognized by The NarL protein.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where multiple binding sites are recognized by Most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where multiple binding sites were recognized by Most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where sequence(YPYDVPDYA) at a 1:500 dilution are recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim).</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where sequence(YPYDVPDYA) at a 1:500 dilution were recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim).</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where short motifs within the protected region are recognized by the proteins.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where short motifs within the protected region were recognized by the proteins.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where the STAT1 N-terminus are recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where the STAT1 N-terminus were recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where the different nonmuscle myosin heavy chain isoforms (A and B) are recognized by four different specific antibodies.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where the different nonmuscle myosin heavy chain isoforms (A and B) were recognized by four different specific antibodies.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where two sites in tsx-p2 are recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where two sites in tsx-p2 were recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with A monoclonal antibody recognizing the STAT1 N-terminus, and by western blotting.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with A monoclonal antibody which recognized the STAT1 N-terminus, and by western blotting</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with A monoclonal antibody which recognizes the STAT1 N-terminus, and by western blotting</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with Anti-64kD human autoantigen D1 antibodies recognizing a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, and by western blotting.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with Anti-64kD human autoantigen D1 antibodies which recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, and by western blotting</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with Anti-64kD human autoantigen D1 antibodies which recognizes a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, and by western blotting</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with Most regulators belonging to the AraC/XylS family recognizing multiple binding sites, and by western blotting.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with Most regulators belonging to the AraC/XylS family which recognized multiple binding sites, and by western blotting</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with Most regulators belonging to the AraC/XylS family which recognizes multiple binding sites, and by western blotting</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with The NarL protein recognizing heptamers in other arrangements, and by western blotting.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with The NarL protein which recognized heptamers in other arrangements, and by western blotting</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with The NarL protein which recognizes heptamers in other arrangements, and by western blotting</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognizing sequence(YPYDVPDYA) at a 1:500 dilution, and by western blotting.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) which recognized sequence(YPYDVPDYA) at a 1:500 dilution, and by western blotting</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) which recognizes sequence(YPYDVPDYA) at a 1:500 dilution, and by western blotting</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with affinity-purified polyclonal anti-LMP-1 antiserum recognizing epitopes in the C-terminus of LMP-1 at a 1:200 dilution, and by western blotting.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with affinity-purified polyclonal anti-LMP-1 antiserum which recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution, and by western blotting</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with affinity-purified polyclonal anti-LMP-1 antiserum which recognizes epitopes in the C-terminus of LMP-1 at a 1:200 dilution, and by western blotting</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-Stat3 pAb recognizing The lower form of Stat3, Stat3Beta, and by western blotting.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-Stat3 pAb which recognized The lower form of Stat3, Stat3Beta, and by western blotting</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-Stat3 pAb which recognizes The lower form of Stat3, Stat3Beta, and by western blotting</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with four different specific antibodies recognizing the different nonmuscle myosin heavy chain isoforms (A and B), and by western blotting.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with four different specific antibodies which recognized the different nonmuscle myosin heavy chain isoforms (A and B), and by western blotting</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with four different specific antibodies which recognizes the different nonmuscle myosin heavy chain isoforms (A and B), and by western blotting</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with rabbit polyclonal anti-CD40 antiserum recognizing C-terminus of CD40 at a 1:500 dilution, and by western blotting.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with rabbit polyclonal anti-CD40 antiserum which recognized C-terminus of CD40 at a 1:500 dilution, and by western blotting</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with rabbit polyclonal anti-CD40 antiserum which recognizes C-terminus of CD40 at a 1:500 dilution, and by western blotting</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the cAMP-CRP activator complex recognizing two sites in tsx-p2, and by western blotting.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the cAMP-CRP activator complex which recognized two sites in tsx-p2, and by western blotting</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the cAMP-CRP activator complex which recognizes two sites in tsx-p2, and by western blotting</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the proteins recognizing short motifs within the protected region, and by western blotting.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the proteins which recognized short motifs within the protected region, and by western blotting</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the proteins which recognizes short motifs within the protected region, and by western blotting</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with this antibody in PKR+/+MEFs recognizing The two forms of Stat3 (Stat3fm and Stat3sm), and by western blotting.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with this antibody in PKR+/+MEFs which recognized The two forms of Stat3 (Stat3fm and Stat3sm), and by western blotting</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with this antibody in PKR+/+MEFs which recognizes The two forms of Stat3 (Stat3fm and Stat3sm), and by western blotting</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>Most regulators belonging to the AraC/XylS family also binds to these 7-2-7 sites but, unlike NarP, also recognizes multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>Most regulators belonging to the AraC/XylS family also bound to these 7-2-7 sites but, unlike NarP, also recognized multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>Most regulators belonging to the AraC/XylS family has also bound to these 7-2-7 sites but, unlike NarP, has also recognized multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>Most regulators belonging to the AraC/XylS family recognize specifically multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>Most regulators belonging to the AraC/XylS family recognized specifically multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>Most regulators belonging to the AraC/XylS family recognizing multiple binding sites was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>Most regulators belonging to the AraC/XylS family which has recognized multiple binding sites was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>Most regulators belonging to the AraC/XylS family which recognizes multiple binding sites is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>Most regulators belonging to the AraC/XylS family will binds to these 7-2-7 sites but, unlike NarP, will also recognize multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>The NarL protein are able to recognize heptamers in other arrangements in the regulated promoters.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>The NarL protein can recognize heptamers in other arrangements in the regulated promoters.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>The NarL protein have recognized heptamers in other arrangements in the regulated promoters.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>The NarL protein recognize heptamers in other arrangements in the regulated promoters.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>The NarL protein recognize specifically heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>The NarL protein recognized heptamers in other arrangements in the regulated promoters.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>The NarL protein recognized specifically heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>The NarL protein recognizing heptamers in other arrangements was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>The NarL protein which has recognized heptamers in other arrangements was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>The NarL protein which recognizes heptamers in other arrangements is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>The NarL protein will recognize heptamers in other arrangements in the regulated promoters.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>The The lower form of Stat3, Stat3Beta is recognized by anti-Stat3 pAb that blots were probed with.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>The The two forms of Stat3 (Stat3fm and Stat3sm) is recognized by this antibody in PKR+/+MEFs that blots were probed with.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>The a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle is recognized by Anti-64kD human autoantigen D1 antibodies that blots were probed with.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>The epitopes in the C-terminus of LMP-1 at a 1:200 dilution is recognized by affinity-purified polyclonal anti-LMP-1 antiserum that blots were probed with.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>The heptamers in other arrangements is recognized by The NarL protein that blots were probed with.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>The lower form of Stat3, Stat3Beta are recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>The lower form of Stat3, Stat3Beta recognized by anti-Stat3 pAb are indicated.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>The lower form of Stat3, Stat3Beta that are recognized by anti-Stat3 pAb are indicated.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>The lower form of Stat3, Stat3Beta that have been recognized by anti-Stat3 pAb are indicated.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>The lower form of Stat3, Stat3Beta that were recognized by anti-Stat3 pAb are indicated.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>The lower form of Stat3, Stat3Beta that will be recognized by anti-Stat3 pAb are indicated.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>The lower form of Stat3, Stat3Beta were recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>The lower form of Stat3, Stat3Beta which can be recognized by anti-Stat3 pAb are indicated.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>The lower form of Stat3, Stat3Beta which were recognized by anti-Stat3 pAb are indicated.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>The multiple binding sites is recognized by Most regulators belonging to the AraC/XylS family that blots were probed with.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>The short motifs within the protected region is recognized by the proteins that blots were probed with.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>The the STAT1 N-terminus is recognized by A monoclonal antibody that blots were probed with.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>The the STAT1 N-terminus is recognized by a monoclonal antibody that blots were probed with.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>The the different nonmuscle myosin heavy chain isoforms (A and B) is recognized by four different specific antibodies that blots were probed with.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm) are recognized by this antibody in PKR+/+MEFs.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm) were recognized by this antibody in PKR+/+MEFs.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm), cannot be recognized in the immunoprecipitaiton with this antibody in PKR+/+MEFs as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm), could not be recognized in the immunoprecipitaiton with this antibody in PKR+/+MEFs as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm), has not been recognized in the immunoprecipitaiton with this antibody in PKR+/+MEFs as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm), is not recognized in the immunoprecipitaiton with this antibody in PKR+/+MEFs as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm), was not recognized in the immunoprecipitaiton with this antibody in PKR+/+MEFs as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm), will not be recognized in the immunoprecipitaiton with this antibody in PKR+/+MEFs as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>The two sites in tsx-p2 is recognized by the cAMP-CRP activator complex that blots were probed with.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>These bands can be detected with A monoclonal antibody recognizing the STAT1 N-terminus</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>These bands can be detected with A monoclonal antibody that recognize the STAT1 N-terminus</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>These bands can be detected with A monoclonal antibody that recognized the STAT1 N-terminus</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>These bands can be detected with A monoclonal antibody which have recognized the STAT1 N-terminus</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>These bands can be detected with A monoclonal antibody which recognize the STAT1 N-terminus</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>These bands can be detected with Anti-64kD human autoantigen D1 antibodies recognizing a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>These bands can be detected with Anti-64kD human autoantigen D1 antibodies that recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>These bands can be detected with Anti-64kD human autoantigen D1 antibodies that recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>These bands can be detected with Anti-64kD human autoantigen D1 antibodies which have recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>These bands can be detected with Anti-64kD human autoantigen D1 antibodies which recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>These bands can be detected with Most regulators belonging to the AraC/XylS family recognizing multiple binding sites</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>These bands can be detected with Most regulators belonging to the AraC/XylS family that recognize multiple binding sites</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>These bands can be detected with Most regulators belonging to the AraC/XylS family that recognized multiple binding sites</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>These bands can be detected with Most regulators belonging to the AraC/XylS family which have recognized multiple binding sites</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>These bands can be detected with Most regulators belonging to the AraC/XylS family which recognize multiple binding sites</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>These bands can be detected with The NarL protein recognizing heptamers in other arrangements</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>These bands can be detected with The NarL protein that recognize heptamers in other arrangements</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>These bands can be detected with The NarL protein that recognized heptamers in other arrangements</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>These bands can be detected with The NarL protein which have recognized heptamers in other arrangements</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>These bands can be detected with The NarL protein which recognize heptamers in other arrangements</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>These bands can be detected with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognizing sequence(YPYDVPDYA) at a 1:500 dilution</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>These bands can be detected with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) that recognize sequence(YPYDVPDYA) at a 1:500 dilution</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>These bands can be detected with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) that recognized sequence(YPYDVPDYA) at a 1:500 dilution</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>These bands can be detected with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) which have recognized sequence(YPYDVPDYA) at a 1:500 dilution</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>These bands can be detected with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) which recognize sequence(YPYDVPDYA) at a 1:500 dilution</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>These bands can be detected with a monoclonal antibody recognizing the STAT1 N-terminus</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>These bands can be detected with a monoclonal antibody that recognize the STAT1 N-terminus</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>These bands can be detected with a monoclonal antibody that recognized the STAT1 N-terminus</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>These bands can be detected with a monoclonal antibody which have recognized the STAT1 N-terminus</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>These bands can be detected with a monoclonal antibody which recognize the STAT1 N-terminus</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>These bands can be detected with affinity-purified polyclonal anti-LMP-1 antiserum recognizing epitopes in the C-terminus of LMP-1 at a 1:200 dilution</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>These bands can be detected with affinity-purified polyclonal anti-LMP-1 antiserum that recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>These bands can be detected with affinity-purified polyclonal anti-LMP-1 antiserum that recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>These bands can be detected with affinity-purified polyclonal anti-LMP-1 antiserum which have recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>These bands can be detected with affinity-purified polyclonal anti-LMP-1 antiserum which recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>These bands can be detected with anti-Stat3 pAb recognizing The lower form of Stat3, Stat3Beta</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>These bands can be detected with anti-Stat3 pAb that recognize The lower form of Stat3, Stat3Beta</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>These bands can be detected with anti-Stat3 pAb that recognized The lower form of Stat3, Stat3Beta</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>These bands can be detected with anti-Stat3 pAb which have recognized The lower form of Stat3, Stat3Beta</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>These bands can be detected with anti-Stat3 pAb which recognize The lower form of Stat3, Stat3Beta</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>These bands can be detected with rabbit polyclonal anti-CD40 antiserum recognizing C-terminus of CD40 at a 1:500 dilution</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>These bands can be detected with rabbit polyclonal anti-CD40 antiserum that recognize C-terminus of CD40 at a 1:500 dilution</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>These bands can be detected with rabbit polyclonal anti-CD40 antiserum that recognized C-terminus of CD40 at a 1:500 dilution</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>These bands can be detected with rabbit polyclonal anti-CD40 antiserum which have recognized C-terminus of CD40 at a 1:500 dilution</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>These bands can be detected with rabbit polyclonal anti-CD40 antiserum which recognize C-terminus of CD40 at a 1:500 dilution</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>These bands can be detected with the cAMP-CRP activator complex recognizing two sites in tsx-p2</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>These bands can be detected with the cAMP-CRP activator complex that recognize two sites in tsx-p2</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>These bands can be detected with the cAMP-CRP activator complex that recognized two sites in tsx-p2</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>These bands can be detected with the cAMP-CRP activator complex which have recognized two sites in tsx-p2</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>These bands can be detected with the cAMP-CRP activator complex which recognize two sites in tsx-p2</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>These bands can be detected with the proteins recognizing short motifs within the protected region</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>These bands can be detected with the proteins that recognize short motifs within the protected region</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>These bands can be detected with the proteins that recognized short motifs within the protected region</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>These bands can be detected with the proteins which have recognized short motifs within the protected region</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>These bands can be detected with the proteins which recognize short motifs within the protected region</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>These bands can be detected with this antibody in PKR+/+MEFs recognizing The two forms of Stat3 (Stat3fm and Stat3sm)</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>These bands can be detected with this antibody in PKR+/+MEFs that recognize The two forms of Stat3 (Stat3fm and Stat3sm)</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>These bands can be detected with this antibody in PKR+/+MEFs that recognized The two forms of Stat3 (Stat3fm and Stat3sm)</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>These bands can be detected with this antibody in PKR+/+MEFs which have recognized The two forms of Stat3 (Stat3fm and Stat3sm)</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>These bands can be detected with this antibody in PKR+/+MEFs which recognize The two forms of Stat3 (Stat3fm and Stat3sm)</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>We show that A monoclonal antibody has recognized the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>We show that A monoclonal antibody recognized the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>We show that A monoclonal antibody recognizes the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>We show that A monoclonal antibody will recognize the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>We show that Anti-64kD human autoantigen D1 antibodies has recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>We show that Anti-64kD human autoantigen D1 antibodies recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>We show that Anti-64kD human autoantigen D1 antibodies recognizes a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>We show that Anti-64kD human autoantigen D1 antibodies will recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>We show that Most regulators belonging to the AraC/XylS family has recognized multiple binding sites that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>We show that Most regulators belonging to the AraC/XylS family recognized multiple binding sites that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>We show that Most regulators belonging to the AraC/XylS family recognizes multiple binding sites that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>We show that Most regulators belonging to the AraC/XylS family will recognize multiple binding sites that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>We show that The NarL protein has recognized heptamers in other arrangements that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>We show that The NarL protein recognized heptamers in other arrangements that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>We show that The NarL protein recognizes heptamers in other arrangements that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>We show that The NarL protein will recognize heptamers in other arrangements that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>We show that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) has recognized sequence(YPYDVPDYA) at a 1:500 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>We show that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognized sequence(YPYDVPDYA) at a 1:500 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>We show that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognizes sequence(YPYDVPDYA) at a 1:500 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>We show that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) will recognize sequence(YPYDVPDYA) at a 1:500 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>We show that a monoclonal antibody has recognized the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>We show that a monoclonal antibody recognized the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>We show that a monoclonal antibody recognizes the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>We show that a monoclonal antibody will recognize the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>We show that affinity-purified polyclonal anti-LMP-1 antiserum has recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>We show that affinity-purified polyclonal anti-LMP-1 antiserum recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>We show that affinity-purified polyclonal anti-LMP-1 antiserum recognizes epitopes in the C-terminus of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>We show that affinity-purified polyclonal anti-LMP-1 antiserum will recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>We show that anti-Stat3 pAb has recognized The lower form of Stat3, Stat3Beta that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>We show that anti-Stat3 pAb recognized The lower form of Stat3, Stat3Beta that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>We show that anti-Stat3 pAb recognizes The lower form of Stat3, Stat3Beta that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>We show that anti-Stat3 pAb will recognize The lower form of Stat3, Stat3Beta that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>We show that four different specific antibodies has recognized the different nonmuscle myosin heavy chain isoforms (A and B) that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>We show that four different specific antibodies recognized the different nonmuscle myosin heavy chain isoforms (A and B) that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>We show that four different specific antibodies recognizes the different nonmuscle myosin heavy chain isoforms (A and B) that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>We show that four different specific antibodies will recognize the different nonmuscle myosin heavy chain isoforms (A and B) that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>We show that rabbit polyclonal anti-CD40 antiserum has recognized C-terminus of CD40 at a 1:500 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>We show that rabbit polyclonal anti-CD40 antiserum recognized C-terminus of CD40 at a 1:500 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>We show that rabbit polyclonal anti-CD40 antiserum recognizes C-terminus of CD40 at a 1:500 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>We show that rabbit polyclonal anti-CD40 antiserum will recognize C-terminus of CD40 at a 1:500 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>We show that the proteins has recognized short motifs within the protected region that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>We show that the proteins recognized short motifs within the protected region that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>We show that the proteins recognizes short motifs within the protected region that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>We show that the proteins will recognize short motifs within the protected region that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>We show that this antibody in PKR+/+MEFs has recognized The two forms of Stat3 (Stat3fm and Stat3sm) that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>We show that this antibody in PKR+/+MEFs recognized The two forms of Stat3 (Stat3fm and Stat3sm) that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>We show that this antibody in PKR+/+MEFs recognizes The two forms of Stat3 (Stat3fm and Stat3sm) that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>We show that this antibody in PKR+/+MEFs will recognize The two forms of Stat3 (Stat3fm and Stat3sm) that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) also binds to these 7-2-7 sites but, unlike NarP, also recognizes sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) also bound to these 7-2-7 sites but, unlike NarP, also recognized sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) are able to recognize sequence(YPYDVPDYA) at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) can recognize sequence(YPYDVPDYA) at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) has also bound to these 7-2-7 sites but, unlike NarP, has also recognized sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) have recognized sequence(YPYDVPDYA) at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognize sequence(YPYDVPDYA) at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognize specifically sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognized sequence(YPYDVPDYA) at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognized specifically sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognizing sequence(YPYDVPDYA) at a 1:500 dilution was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) which has recognized sequence(YPYDVPDYA) at a 1:500 dilution was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) which recognizes sequence(YPYDVPDYA) at a 1:500 dilution is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) will binds to these 7-2-7 sites but, unlike NarP, will also recognize sequence(YPYDVPDYA) at a 1:500 dilution.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) will recognize sequence(YPYDVPDYA) at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle are recognized by Anti-64kD human autoantigen D1 antibodies.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle recognized by Anti-64kD human autoantigen D1 antibodies are indicated.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that are recognized by Anti-64kD human autoantigen D1 antibodies are indicated.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that have been recognized by Anti-64kD human autoantigen D1 antibodies are indicated.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that were recognized by Anti-64kD human autoantigen D1 antibodies are indicated.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that will be recognized by Anti-64kD human autoantigen D1 antibodies are indicated.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle were recognized by Anti-64kD human autoantigen D1 antibodies.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle which can be recognized by Anti-64kD human autoantigen D1 antibodies are indicated.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle which were recognized by Anti-64kD human autoantigen D1 antibodies are indicated.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, cannot be recognized in the immunoprecipitaiton with Anti-64kD human autoantigen D1 antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, could not be recognized in the immunoprecipitaiton with Anti-64kD human autoantigen D1 antibodies as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, has not been recognized in the immunoprecipitaiton with Anti-64kD human autoantigen D1 antibodies as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, is not recognized in the immunoprecipitaiton with Anti-64kD human autoantigen D1 antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, was not recognized in the immunoprecipitaiton with Anti-64kD human autoantigen D1 antibodies as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, will not be recognized in the immunoprecipitaiton with Anti-64kD human autoantigen D1 antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>a monoclonal antibody also binds to these 7-2-7 sites but, unlike NarP, also recognizes the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>a monoclonal antibody also bound to these 7-2-7 sites but, unlike NarP, also recognized the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>a monoclonal antibody are able to recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>a monoclonal antibody can recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>a monoclonal antibody has also bound to these 7-2-7 sites but, unlike NarP, has also recognized the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>a monoclonal antibody have recognized the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>a monoclonal antibody recognize specifically the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>a monoclonal antibody recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>a monoclonal antibody recognized specifically the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>a monoclonal antibody recognized the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>a monoclonal antibody recognizing the STAT1 N-terminus was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>a monoclonal antibody which has recognized the STAT1 N-terminus was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>a monoclonal antibody which recognizes the STAT1 N-terminus is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>a monoclonal antibody will binds to these 7-2-7 sites but, unlike NarP, will also recognize the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>a monoclonal antibody will recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum also binds to these 7-2-7 sites but, unlike NarP, also recognizes epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum also bound to these 7-2-7 sites but, unlike NarP, also recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum are able to recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum can recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum has also bound to these 7-2-7 sites but, unlike NarP, has also recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum have recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum recognize specifically epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum recognized specifically epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum recognizing epitopes in the C-terminus of LMP-1 at a 1:200 dilution was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum which has recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum which recognizes epitopes in the C-terminus of LMP-1 at a 1:200 dilution is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum will binds to these 7-2-7 sites but, unlike NarP, will also recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum will recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>anti-Stat3 pAb also binds to these 7-2-7 sites but, unlike NarP, also recognizes The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>anti-Stat3 pAb also bound to these 7-2-7 sites but, unlike NarP, also recognized The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>anti-Stat3 pAb are able to recognize The lower form of Stat3, Stat3Beta in the regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>anti-Stat3 pAb can recognize The lower form of Stat3, Stat3Beta in the regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>anti-Stat3 pAb has also bound to these 7-2-7 sites but, unlike NarP, has also recognized The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>anti-Stat3 pAb have recognized The lower form of Stat3, Stat3Beta in the regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>anti-Stat3 pAb recognize The lower form of Stat3, Stat3Beta in the regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>anti-Stat3 pAb recognize specifically The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>anti-Stat3 pAb recognized The lower form of Stat3, Stat3Beta in the regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>anti-Stat3 pAb recognized specifically The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>anti-Stat3 pAb recognizing The lower form of Stat3, Stat3Beta was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>anti-Stat3 pAb which has recognized The lower form of Stat3, Stat3Beta was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>anti-Stat3 pAb which recognizes The lower form of Stat3, Stat3Beta is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>anti-Stat3 pAb will binds to these 7-2-7 sites but, unlike NarP, will also recognize The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>anti-Stat3 pAb will recognize The lower form of Stat3, Stat3Beta in the regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution are recognized by affinity-purified polyclonal anti-LMP-1 antiserum.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution recognized by affinity-purified polyclonal anti-LMP-1 antiserum are indicated.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution that are recognized by affinity-purified polyclonal anti-LMP-1 antiserum are indicated.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution that have been recognized by affinity-purified polyclonal anti-LMP-1 antiserum are indicated.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution that were recognized by affinity-purified polyclonal anti-LMP-1 antiserum are indicated.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution that will be recognized by affinity-purified polyclonal anti-LMP-1 antiserum are indicated.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution were recognized by affinity-purified polyclonal anti-LMP-1 antiserum.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution which can be recognized by affinity-purified polyclonal anti-LMP-1 antiserum are indicated.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution which were recognized by affinity-purified polyclonal anti-LMP-1 antiserum are indicated.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution, cannot be recognized in the immunoprecipitaiton with affinity-purified polyclonal anti-LMP-1 antiserum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution, could not be recognized in the immunoprecipitaiton with affinity-purified polyclonal anti-LMP-1 antiserum as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution, has not been recognized in the immunoprecipitaiton with affinity-purified polyclonal anti-LMP-1 antiserum as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution, is not recognized in the immunoprecipitaiton with affinity-purified polyclonal anti-LMP-1 antiserum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution, was not recognized in the immunoprecipitaiton with affinity-purified polyclonal anti-LMP-1 antiserum as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution, will not be recognized in the immunoprecipitaiton with affinity-purified polyclonal anti-LMP-1 antiserum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>four different specific antibodies also binds to these 7-2-7 sites but, unlike NarP, also recognizes the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>four different specific antibodies also bound to these 7-2-7 sites but, unlike NarP, also recognized the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>four different specific antibodies are able to recognize the different nonmuscle myosin heavy chain isoforms (A and B) in the regulated promoters.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>four different specific antibodies can recognize the different nonmuscle myosin heavy chain isoforms (A and B) in the regulated promoters.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>four different specific antibodies has also bound to these 7-2-7 sites but, unlike NarP, has also recognized the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>four different specific antibodies have recognized the different nonmuscle myosin heavy chain isoforms (A and B) in the regulated promoters.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>four different specific antibodies recognize specifically the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>four different specific antibodies recognize the different nonmuscle myosin heavy chain isoforms (A and B) in the regulated promoters.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>four different specific antibodies recognized specifically the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>four different specific antibodies recognized the different nonmuscle myosin heavy chain isoforms (A and B) in the regulated promoters.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>four different specific antibodies recognizing the different nonmuscle myosin heavy chain isoforms (A and B) was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>four different specific antibodies which has recognized the different nonmuscle myosin heavy chain isoforms (A and B) was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>four different specific antibodies which recognizes the different nonmuscle myosin heavy chain isoforms (A and B) is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>four different specific antibodies will binds to these 7-2-7 sites but, unlike NarP, will also recognize the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>four different specific antibodies will recognize the different nonmuscle myosin heavy chain isoforms (A and B) in the regulated promoters.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>heptamers in other arrangements are recognized by The NarL protein.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>heptamers in other arrangements recognized by The NarL protein are indicated.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>heptamers in other arrangements that are recognized by The NarL protein are indicated.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>heptamers in other arrangements that have been recognized by The NarL protein are indicated.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>heptamers in other arrangements that were recognized by The NarL protein are indicated.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>heptamers in other arrangements that will be recognized by The NarL protein are indicated.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>heptamers in other arrangements were recognized by The NarL protein.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>heptamers in other arrangements which can be recognized by The NarL protein are indicated.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>heptamers in other arrangements which were recognized by The NarL protein are indicated.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>heptamers in other arrangements, cannot be recognized in the immunoprecipitaiton with The NarL protein as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>heptamers in other arrangements, could not be recognized in the immunoprecipitaiton with The NarL protein as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>heptamers in other arrangements, has not been recognized in the immunoprecipitaiton with The NarL protein as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>heptamers in other arrangements, is not recognized in the immunoprecipitaiton with The NarL protein as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>heptamers in other arrangements, was not recognized in the immunoprecipitaiton with The NarL protein as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>heptamers in other arrangements, will not be recognized in the immunoprecipitaiton with The NarL protein as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>multiple binding sites are recognized by Most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>multiple binding sites recognized by Most regulators belonging to the AraC/XylS family are indicated.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>multiple binding sites that are recognized by Most regulators belonging to the AraC/XylS family are indicated.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>multiple binding sites that have been recognized by Most regulators belonging to the AraC/XylS family are indicated.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>multiple binding sites that were recognized by Most regulators belonging to the AraC/XylS family are indicated.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>multiple binding sites that will be recognized by Most regulators belonging to the AraC/XylS family are indicated.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>multiple binding sites were recognized by Most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>multiple binding sites which can be recognized by Most regulators belonging to the AraC/XylS family are indicated.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>multiple binding sites which were recognized by Most regulators belonging to the AraC/XylS family are indicated.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>multiple binding sites, cannot be recognized in the immunoprecipitaiton with Most regulators belonging to the AraC/XylS family as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>multiple binding sites, could not be recognized in the immunoprecipitaiton with Most regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>multiple binding sites, has not been recognized in the immunoprecipitaiton with Most regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>multiple binding sites, is not recognized in the immunoprecipitaiton with Most regulators belonging to the AraC/XylS family as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>multiple binding sites, was not recognized in the immunoprecipitaiton with Most regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>multiple binding sites, will not be recognized in the immunoprecipitaiton with Most regulators belonging to the AraC/XylS family as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>rabbit polyclonal anti-CD40 antiserum also binds to these 7-2-7 sites but, unlike NarP, also recognizes C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>rabbit polyclonal anti-CD40 antiserum also bound to these 7-2-7 sites but, unlike NarP, also recognized C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>rabbit polyclonal anti-CD40 antiserum are able to recognize C-terminus of CD40 at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>rabbit polyclonal anti-CD40 antiserum can recognize C-terminus of CD40 at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>rabbit polyclonal anti-CD40 antiserum has also bound to these 7-2-7 sites but, unlike NarP, has also recognized C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>rabbit polyclonal anti-CD40 antiserum have recognized C-terminus of CD40 at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>rabbit polyclonal anti-CD40 antiserum recognize C-terminus of CD40 at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>rabbit polyclonal anti-CD40 antiserum recognize specifically C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>rabbit polyclonal anti-CD40 antiserum recognized C-terminus of CD40 at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>rabbit polyclonal anti-CD40 antiserum recognized specifically C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>rabbit polyclonal anti-CD40 antiserum recognizing C-terminus of CD40 at a 1:500 dilution was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>rabbit polyclonal anti-CD40 antiserum which has recognized C-terminus of CD40 at a 1:500 dilution was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>rabbit polyclonal anti-CD40 antiserum which recognizes C-terminus of CD40 at a 1:500 dilution is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>rabbit polyclonal anti-CD40 antiserum will binds to these 7-2-7 sites but, unlike NarP, will also recognize C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>rabbit polyclonal anti-CD40 antiserum will recognize C-terminus of CD40 at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution are recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim).</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) are indicated.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution that are recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) are indicated.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution that have been recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) are indicated.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution that were recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) are indicated.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution that will be recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) are indicated.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution were recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim).</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution which can be recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) are indicated.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution which were recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) are indicated.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution, cannot be recognized in the immunoprecipitaiton with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution, could not be recognized in the immunoprecipitaiton with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution, has not been recognized in the immunoprecipitaiton with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution, is not recognized in the immunoprecipitaiton with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution, was not recognized in the immunoprecipitaiton with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution, will not be recognized in the immunoprecipitaiton with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>short motifs within the protected region are recognized by the proteins.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>short motifs within the protected region recognized by the proteins are indicated.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>short motifs within the protected region that are recognized by the proteins are indicated.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>short motifs within the protected region that have been recognized by the proteins are indicated.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>short motifs within the protected region that were recognized by the proteins are indicated.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>short motifs within the protected region that will be recognized by the proteins are indicated.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>short motifs within the protected region were recognized by the proteins.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>short motifs within the protected region which can be recognized by the proteins are indicated.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>short motifs within the protected region which were recognized by the proteins are indicated.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>short motifs within the protected region, cannot be recognized in the immunoprecipitaiton with the proteins as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>short motifs within the protected region, could not be recognized in the immunoprecipitaiton with the proteins as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>short motifs within the protected region, has not been recognized in the immunoprecipitaiton with the proteins as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>short motifs within the protected region, is not recognized in the immunoprecipitaiton with the proteins as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>short motifs within the protected region, was not recognized in the immunoprecipitaiton with the proteins as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>short motifs within the protected region, will not be recognized in the immunoprecipitaiton with the proteins as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>the STAT1 N-terminus are recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>the STAT1 N-terminus are recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>the STAT1 N-terminus recognized by A monoclonal antibody are indicated.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>the STAT1 N-terminus recognized by a monoclonal antibody are indicated.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>the STAT1 N-terminus that are recognized by A monoclonal antibody are indicated.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>the STAT1 N-terminus that are recognized by a monoclonal antibody are indicated.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>the STAT1 N-terminus that have been recognized by A monoclonal antibody are indicated.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>the STAT1 N-terminus that have been recognized by a monoclonal antibody are indicated.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>the STAT1 N-terminus that were recognized by A monoclonal antibody are indicated.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>the STAT1 N-terminus that were recognized by a monoclonal antibody are indicated.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>the STAT1 N-terminus that will be recognized by A monoclonal antibody are indicated.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>the STAT1 N-terminus that will be recognized by a monoclonal antibody are indicated.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>the STAT1 N-terminus were recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>the STAT1 N-terminus were recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>the STAT1 N-terminus which can be recognized by A monoclonal antibody are indicated.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>the STAT1 N-terminus which can be recognized by a monoclonal antibody are indicated.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>the STAT1 N-terminus which were recognized by A monoclonal antibody are indicated.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>the STAT1 N-terminus which were recognized by a monoclonal antibody are indicated.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>the STAT1 N-terminus, cannot be recognized in the immunoprecipitaiton with A monoclonal antibody as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>the STAT1 N-terminus, cannot be recognized in the immunoprecipitaiton with a monoclonal antibody as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>the STAT1 N-terminus, could not be recognized in the immunoprecipitaiton with A monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>the STAT1 N-terminus, could not be recognized in the immunoprecipitaiton with a monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>the STAT1 N-terminus, has not been recognized in the immunoprecipitaiton with A monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>the STAT1 N-terminus, has not been recognized in the immunoprecipitaiton with a monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>the STAT1 N-terminus, is not recognized in the immunoprecipitaiton with A monoclonal antibody as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>the STAT1 N-terminus, is not recognized in the immunoprecipitaiton with a monoclonal antibody as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>the STAT1 N-terminus, was not recognized in the immunoprecipitaiton with A monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>the STAT1 N-terminus, was not recognized in the immunoprecipitaiton with a monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>the STAT1 N-terminus, will not be recognized in the immunoprecipitaiton with A monoclonal antibody as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>the STAT1 N-terminus, will not be recognized in the immunoprecipitaiton with a monoclonal antibody as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>the cAMP-CRP activator complex also binds to these 7-2-7 sites but, unlike NarP, also recognizes two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>the cAMP-CRP activator complex also bound to these 7-2-7 sites but, unlike NarP, also recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>the cAMP-CRP activator complex are able to recognize two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>the cAMP-CRP activator complex can recognize two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>the cAMP-CRP activator complex has also bound to these 7-2-7 sites but, unlike NarP, has also recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>the cAMP-CRP activator complex have recognized two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>the cAMP-CRP activator complex recognize specifically two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>the cAMP-CRP activator complex recognize two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>the cAMP-CRP activator complex recognized specifically two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>the cAMP-CRP activator complex recognized two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>the cAMP-CRP activator complex recognizing two sites in tsx-p2 was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>the cAMP-CRP activator complex which has recognized two sites in tsx-p2 was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>the cAMP-CRP activator complex which recognizes two sites in tsx-p2 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>the cAMP-CRP activator complex will binds to these 7-2-7 sites but, unlike NarP, will also recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>the cAMP-CRP activator complex will recognize two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B) are recognized by four different specific antibodies.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B) recognized by four different specific antibodies are indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B) that are recognized by four different specific antibodies are indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B) that have been recognized by four different specific antibodies are indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B) that were recognized by four different specific antibodies are indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B) that will be recognized by four different specific antibodies are indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B) were recognized by four different specific antibodies.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B) which can be recognized by four different specific antibodies are indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B) which were recognized by four different specific antibodies are indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B), cannot be recognized in the immunoprecipitaiton with four different specific antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B), could not be recognized in the immunoprecipitaiton with four different specific antibodies as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B), has not been recognized in the immunoprecipitaiton with four different specific antibodies as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B), is not recognized in the immunoprecipitaiton with four different specific antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B), was not recognized in the immunoprecipitaiton with four different specific antibodies as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B), will not be recognized in the immunoprecipitaiton with four different specific antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>the proteins also binds to these 7-2-7 sites but, unlike NarP, also recognizes short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>the proteins also bound to these 7-2-7 sites but, unlike NarP, also recognized short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>the proteins are able to recognize short motifs within the protected region in the regulated promoters.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>the proteins can recognize short motifs within the protected region in the regulated promoters.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>the proteins has also bound to these 7-2-7 sites but, unlike NarP, has also recognized short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>the proteins have recognized short motifs within the protected region in the regulated promoters.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>the proteins recognize short motifs within the protected region in the regulated promoters.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>the proteins recognize specifically short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>the proteins recognized short motifs within the protected region in the regulated promoters.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>the proteins recognized specifically short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>the proteins recognizing short motifs within the protected region was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>the proteins which has recognized short motifs within the protected region was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>the proteins which recognizes short motifs within the protected region is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>the proteins will binds to these 7-2-7 sites but, unlike NarP, will also recognize short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>the proteins will recognize short motifs within the protected region in the regulated promoters.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>this antibody in PKR+/+MEFs also binds to these 7-2-7 sites but, unlike NarP, also recognizes The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>this antibody in PKR+/+MEFs also bound to these 7-2-7 sites but, unlike NarP, also recognized The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>this antibody in PKR+/+MEFs are able to recognize The two forms of Stat3 (Stat3fm and Stat3sm) in the regulated promoters.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>this antibody in PKR+/+MEFs can recognize The two forms of Stat3 (Stat3fm and Stat3sm) in the regulated promoters.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>this antibody in PKR+/+MEFs has also bound to these 7-2-7 sites but, unlike NarP, has also recognized The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>this antibody in PKR+/+MEFs have recognized The two forms of Stat3 (Stat3fm and Stat3sm) in the regulated promoters.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>this antibody in PKR+/+MEFs recognize The two forms of Stat3 (Stat3fm and Stat3sm) in the regulated promoters.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>this antibody in PKR+/+MEFs recognize specifically The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>this antibody in PKR+/+MEFs recognized The two forms of Stat3 (Stat3fm and Stat3sm) in the regulated promoters.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>this antibody in PKR+/+MEFs recognized specifically The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>this antibody in PKR+/+MEFs recognizing The two forms of Stat3 (Stat3fm and Stat3sm) was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>this antibody in PKR+/+MEFs which has recognized The two forms of Stat3 (Stat3fm and Stat3sm) was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>this antibody in PKR+/+MEFs which recognizes The two forms of Stat3 (Stat3fm and Stat3sm) is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>this antibody in PKR+/+MEFs will binds to these 7-2-7 sites but, unlike NarP, will also recognize The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>this antibody in PKR+/+MEFs will recognize The two forms of Stat3 (Stat3fm and Stat3sm) in the regulated promoters.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>two sites in tsx-p2 recognized by the cAMP-CRP activator complex are indicated.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>two sites in tsx-p2 that are recognized by the cAMP-CRP activator complex are indicated.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>two sites in tsx-p2 that have been recognized by the cAMP-CRP activator complex are indicated.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>two sites in tsx-p2 that were recognized by the cAMP-CRP activator complex are indicated.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>two sites in tsx-p2 that will be recognized by the cAMP-CRP activator complex are indicated.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>two sites in tsx-p2 which can be recognized by the cAMP-CRP activator complex are indicated.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>two sites in tsx-p2 which were recognized by the cAMP-CRP activator complex are indicated.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>two sites in tsx-p2, cannot be recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>two sites in tsx-p2, could not be recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>two sites in tsx-p2, has not been recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>two sites in tsx-p2, is not recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>two sites in tsx-p2, was not recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>two sites in tsx-p2, will not be recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>A number of Ags are recognized by class I-restricted melanoma-specific T cells.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>A number of Ags recognized by class I-restricted melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>A number of Ags that are recognized by class I-restricted melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>A number of Ags that have been recognized by class I-restricted melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>A number of Ags that were recognized by class I-restricted melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>A number of Ags that will be recognized by class I-restricted melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>A number of Ags were recognized by class I-restricted melanoma-specific T cells.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>A number of Ags which can be recognized by class I-restricted melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>A number of Ags which were recognized by class I-restricted melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>A number of Ags, cannot be recognized in the immunoprecipitaiton with class I-restricted melanoma-specific T cells as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>A number of Ags, could not be recognized in the immunoprecipitaiton with class I-restricted melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>A number of Ags, has not been recognized in the immunoprecipitaiton with class I-restricted melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>A number of Ags, is not recognized in the immunoprecipitaiton with class I-restricted melanoma-specific T cells as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>A number of Ags, was not recognized in the immunoprecipitaiton with class I-restricted melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>A number of Ags, will not be recognized in the immunoprecipitaiton with class I-restricted melanoma-specific T cells as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>Blots were probed with class I-restricted melanoma-specific T cells recognizing A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>Blots were probed with class I-restricted melanoma-specific T cells that can recognize A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>Blots were probed with class I-restricted melanoma-specific T cells that recognized A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>Blots were probed with class I-restricted melanoma-specific T cells that recognizes A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>Blots were probed with class I-restricted melanoma-specific T cells that recognizes the A number of Ags, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>Blots were probed with class I-restricted melanoma-specific T cells that recognizes the A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>Blots were probed with either of two monoclonal antibodies recognizing COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>Blots were probed with either of two monoclonal antibodies that can recognize COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>Blots were probed with either of two monoclonal antibodies that recognized COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>Blots were probed with either of two monoclonal antibodies that recognizes COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>Blots were probed with either of two monoclonal antibodies that recognizes the COOH-terminal epitopes, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>Blots were probed with either of two monoclonal antibodies that recognizes the COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>Blots were probed with the RNA-splicing apparatus recognizing the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>Blots were probed with the RNA-splicing apparatus that can recognize the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>Blots were probed with the RNA-splicing apparatus that recognized the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>Blots were probed with the RNA-splicing apparatus that recognizes the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>Blots were probed with the RNA-splicing apparatus that recognizes the the normal splice junction, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>Blots were probed with the RNA-splicing apparatus that recognizes the the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>Blots were probed with the autologous serum recognizing the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>Blots were probed with the autologous serum that can recognize the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>Blots were probed with the autologous serum that recognized the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>Blots were probed with the autologous serum that recognizes the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>Blots were probed with the autologous serum that recognizes the the epitopes, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>Blots were probed with the autologous serum that recognizes the the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>COOH-terminal epitopes are recognized by either of two monoclonal antibodies.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>COOH-terminal epitopes recognized by either of two monoclonal antibodies are indicated.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>COOH-terminal epitopes that are recognized by either of two monoclonal antibodies are indicated.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>COOH-terminal epitopes that have been recognized by either of two monoclonal antibodies are indicated.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>COOH-terminal epitopes that were recognized by either of two monoclonal antibodies are indicated.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>COOH-terminal epitopes that will be recognized by either of two monoclonal antibodies are indicated.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>COOH-terminal epitopes were recognized by either of two monoclonal antibodies.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>COOH-terminal epitopes which can be recognized by either of two monoclonal antibodies are indicated.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>COOH-terminal epitopes which were recognized by either of two monoclonal antibodies are indicated.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>COOH-terminal epitopes, cannot be recognized in the immunoprecipitaiton with either of two monoclonal antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>COOH-terminal epitopes, could not be recognized in the immunoprecipitaiton with either of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>COOH-terminal epitopes, has not been recognized in the immunoprecipitaiton with either of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>COOH-terminal epitopes, is not recognized in the immunoprecipitaiton with either of two monoclonal antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>COOH-terminal epitopes, was not recognized in the immunoprecipitaiton with either of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>COOH-terminal epitopes, will not be recognized in the immunoprecipitaiton with either of two monoclonal antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that class I-restricted melanoma-specific T cells are able to recognize A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that class I-restricted melanoma-specific T cells can recognize A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that class I-restricted melanoma-specific T cells has recognized A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that class I-restricted melanoma-specific T cells recognize A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that class I-restricted melanoma-specific T cells recognized A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that either of two monoclonal antibodies are able to recognize COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that either of two monoclonal antibodies can recognize COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that either of two monoclonal antibodies has recognized COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that either of two monoclonal antibodies recognize COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that either of two monoclonal antibodies recognized COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the RNA-splicing apparatus are able to recognize the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the RNA-splicing apparatus can recognize the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the RNA-splicing apparatus has recognized the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the RNA-splicing apparatus recognize the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the RNA-splicing apparatus recognized the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the autologous serum are able to recognize the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the autologous serum can recognize the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the autologous serum has recognized the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the autologous serum recognize the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the autologous serum recognized the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where A number of Ags are recognized by class I-restricted melanoma-specific T cells.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where A number of Ags were recognized by class I-restricted melanoma-specific T cells.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where COOH-terminal epitopes are recognized by either of two monoclonal antibodies.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where COOH-terminal epitopes were recognized by either of two monoclonal antibodies.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where the epitopes are recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where the epitopes were recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where the normal splice junction are recognized by the RNA-splicing apparatus.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where the normal splice junction were recognized by the RNA-splicing apparatus.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with class I-restricted melanoma-specific T cells recognizing A number of Ags, and by western blotting.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with class I-restricted melanoma-specific T cells which recognized A number of Ags, and by western blotting</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with class I-restricted melanoma-specific T cells which recognizes A number of Ags, and by western blotting</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with either of two monoclonal antibodies recognizing COOH-terminal epitopes, and by western blotting.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with either of two monoclonal antibodies which recognized COOH-terminal epitopes, and by western blotting</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with either of two monoclonal antibodies which recognizes COOH-terminal epitopes, and by western blotting</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the RNA-splicing apparatus recognizing the normal splice junction, and by western blotting.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the RNA-splicing apparatus which recognized the normal splice junction, and by western blotting</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the RNA-splicing apparatus which recognizes the normal splice junction, and by western blotting</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the autologous serum recognizing the epitopes, and by western blotting.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the autologous serum which recognized the epitopes, and by western blotting</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the autologous serum which recognizes the epitopes, and by western blotting</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>The A number of Ags is recognized by class I-restricted melanoma-specific T cells that blots were probed with.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>The COOH-terminal epitopes is recognized by either of two monoclonal antibodies that blots were probed with.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>The the epitopes is recognized by the autologous serum that blots were probed with.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>The the normal splice junction is recognized by the RNA-splicing apparatus that blots were probed with.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>These bands can be detected with class I-restricted melanoma-specific T cells recognizing A number of Ags</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>These bands can be detected with class I-restricted melanoma-specific T cells that recognize A number of Ags</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>These bands can be detected with class I-restricted melanoma-specific T cells that recognized A number of Ags</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>These bands can be detected with class I-restricted melanoma-specific T cells which have recognized A number of Ags</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>These bands can be detected with class I-restricted melanoma-specific T cells which recognize A number of Ags</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>These bands can be detected with either of two monoclonal antibodies recognizing COOH-terminal epitopes</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>These bands can be detected with either of two monoclonal antibodies that recognize COOH-terminal epitopes</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>These bands can be detected with either of two monoclonal antibodies that recognized COOH-terminal epitopes</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>These bands can be detected with either of two monoclonal antibodies which have recognized COOH-terminal epitopes</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>These bands can be detected with either of two monoclonal antibodies which recognize COOH-terminal epitopes</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>These bands can be detected with the RNA-splicing apparatus recognizing the normal splice junction</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>These bands can be detected with the RNA-splicing apparatus that recognize the normal splice junction</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>These bands can be detected with the RNA-splicing apparatus that recognized the normal splice junction</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>These bands can be detected with the RNA-splicing apparatus which have recognized the normal splice junction</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>These bands can be detected with the RNA-splicing apparatus which recognize the normal splice junction</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>These bands can be detected with the autologous serum recognizing the epitopes</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>These bands can be detected with the autologous serum that recognize the epitopes</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>These bands can be detected with the autologous serum that recognized the epitopes</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>These bands can be detected with the autologous serum which have recognized the epitopes</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>These bands can be detected with the autologous serum which recognize the epitopes</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>We show that class I-restricted melanoma-specific T cells has recognized A number of Ags that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>We show that class I-restricted melanoma-specific T cells recognized A number of Ags that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>We show that class I-restricted melanoma-specific T cells recognizes A number of Ags that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>We show that class I-restricted melanoma-specific T cells will recognize A number of Ags that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>We show that either of two monoclonal antibodies has recognized COOH-terminal epitopes that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>We show that either of two monoclonal antibodies recognized COOH-terminal epitopes that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>We show that either of two monoclonal antibodies recognizes COOH-terminal epitopes that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>We show that either of two monoclonal antibodies will recognize COOH-terminal epitopes that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>We show that the RNA-splicing apparatus has recognized the normal splice junction that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>We show that the RNA-splicing apparatus recognized the normal splice junction that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>We show that the RNA-splicing apparatus recognizes the normal splice junction that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>We show that the RNA-splicing apparatus will recognize the normal splice junction that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>We show that the autologous serum has recognized the epitopes that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>We show that the autologous serum recognized the epitopes that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>We show that the autologous serum recognizes the epitopes that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>We show that the autologous serum will recognize the epitopes that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>class I-restricted melanoma-specific T cells also binds to these 7-2-7 sites but, unlike NarP, also recognizes A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>class I-restricted melanoma-specific T cells also bound to these 7-2-7 sites but, unlike NarP, also recognized A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>class I-restricted melanoma-specific T cells are able to recognize A number of Ags in the regulated promoters.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>class I-restricted melanoma-specific T cells can recognize A number of Ags in the regulated promoters.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>class I-restricted melanoma-specific T cells has also bound to these 7-2-7 sites but, unlike NarP, has also recognized A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>class I-restricted melanoma-specific T cells have recognized A number of Ags in the regulated promoters.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>class I-restricted melanoma-specific T cells recognize A number of Ags in the regulated promoters.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>class I-restricted melanoma-specific T cells recognize specifically A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>class I-restricted melanoma-specific T cells recognized A number of Ags in the regulated promoters.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>class I-restricted melanoma-specific T cells recognized specifically A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>class I-restricted melanoma-specific T cells recognizing A number of Ags was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>class I-restricted melanoma-specific T cells which has recognized A number of Ags was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>class I-restricted melanoma-specific T cells which recognizes A number of Ags is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>class I-restricted melanoma-specific T cells will binds to these 7-2-7 sites but, unlike NarP, will also recognize A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>class I-restricted melanoma-specific T cells will recognize A number of Ags in the regulated promoters.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>either of two monoclonal antibodies also binds to these 7-2-7 sites but, unlike NarP, also recognizes COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>either of two monoclonal antibodies also bound to these 7-2-7 sites but, unlike NarP, also recognized COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>either of two monoclonal antibodies are able to recognize COOH-terminal epitopes in the regulated promoters.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>either of two monoclonal antibodies can recognize COOH-terminal epitopes in the regulated promoters.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>either of two monoclonal antibodies has also bound to these 7-2-7 sites but, unlike NarP, has also recognized COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>either of two monoclonal antibodies have recognized COOH-terminal epitopes in the regulated promoters.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>either of two monoclonal antibodies recognize COOH-terminal epitopes in the regulated promoters.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>either of two monoclonal antibodies recognize specifically COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>either of two monoclonal antibodies recognized COOH-terminal epitopes in the regulated promoters.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>either of two monoclonal antibodies recognized specifically COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>either of two monoclonal antibodies recognizing COOH-terminal epitopes was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>either of two monoclonal antibodies which has recognized COOH-terminal epitopes was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>either of two monoclonal antibodies which recognizes COOH-terminal epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>either of two monoclonal antibodies will binds to these 7-2-7 sites but, unlike NarP, will also recognize COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>either of two monoclonal antibodies will recognize COOH-terminal epitopes in the regulated promoters.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>the RNA-splicing apparatus also binds to these 7-2-7 sites but, unlike NarP, also recognizes the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>the RNA-splicing apparatus also bound to these 7-2-7 sites but, unlike NarP, also recognized the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>the RNA-splicing apparatus are able to recognize the normal splice junction in the regulated promoters.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>the RNA-splicing apparatus can recognize the normal splice junction in the regulated promoters.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>the RNA-splicing apparatus has also bound to these 7-2-7 sites but, unlike NarP, has also recognized the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>the RNA-splicing apparatus have recognized the normal splice junction in the regulated promoters.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>the RNA-splicing apparatus recognize specifically the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>the RNA-splicing apparatus recognize the normal splice junction in the regulated promoters.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>the RNA-splicing apparatus recognized specifically the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>the RNA-splicing apparatus recognized the normal splice junction in the regulated promoters.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>the RNA-splicing apparatus recognizing the normal splice junction was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>the RNA-splicing apparatus which has recognized the normal splice junction was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>the RNA-splicing apparatus which recognizes the normal splice junction is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>the RNA-splicing apparatus will binds to these 7-2-7 sites but, unlike NarP, will also recognize the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>the RNA-splicing apparatus will recognize the normal splice junction in the regulated promoters.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>the autologous serum also binds to these 7-2-7 sites but, unlike NarP, also recognizes the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>the autologous serum also bound to these 7-2-7 sites but, unlike NarP, also recognized the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>the autologous serum are able to recognize the epitopes in the regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>the autologous serum can recognize the epitopes in the regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>the autologous serum has also bound to these 7-2-7 sites but, unlike NarP, has also recognized the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>the autologous serum have recognized the epitopes in the regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>the autologous serum recognize specifically the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>the autologous serum recognize the epitopes in the regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>the autologous serum recognized specifically the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>the autologous serum recognized the epitopes in the regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>the autologous serum recognizing the epitopes was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>the autologous serum which has recognized the epitopes was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>the autologous serum which recognizes the epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>the autologous serum will binds to these 7-2-7 sites but, unlike NarP, will also recognize the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>the autologous serum will recognize the epitopes in the regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>the epitopes are recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>the epitopes recognized by the autologous serum are indicated.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>the epitopes that are recognized by the autologous serum are indicated.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>the epitopes that have been recognized by the autologous serum are indicated.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>the epitopes that were recognized by the autologous serum are indicated.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>the epitopes that will be recognized by the autologous serum are indicated.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>the epitopes were recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>the epitopes which can be recognized by the autologous serum are indicated.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>the epitopes which were recognized by the autologous serum are indicated.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>the epitopes, cannot be recognized in the immunoprecipitaiton with the autologous serum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>the epitopes, could not be recognized in the immunoprecipitaiton with the autologous serum as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>the epitopes, has not been recognized in the immunoprecipitaiton with the autologous serum as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>the epitopes, is not recognized in the immunoprecipitaiton with the autologous serum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>the epitopes, was not recognized in the immunoprecipitaiton with the autologous serum as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>the epitopes, will not be recognized in the immunoprecipitaiton with the autologous serum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>the normal splice junction are recognized by the RNA-splicing apparatus.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>the normal splice junction recognized by the RNA-splicing apparatus are indicated.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>the normal splice junction that are recognized by the RNA-splicing apparatus are indicated.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>the normal splice junction that have been recognized by the RNA-splicing apparatus are indicated.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>the normal splice junction that were recognized by the RNA-splicing apparatus are indicated.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>the normal splice junction that will be recognized by the RNA-splicing apparatus are indicated.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>the normal splice junction were recognized by the RNA-splicing apparatus.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>the normal splice junction which can be recognized by the RNA-splicing apparatus are indicated.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>the normal splice junction which were recognized by the RNA-splicing apparatus are indicated.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>the normal splice junction, cannot be recognized in the immunoprecipitaiton with the RNA-splicing apparatus as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>the normal splice junction, could not be recognized in the immunoprecipitaiton with the RNA-splicing apparatus as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>the normal splice junction, has not been recognized in the immunoprecipitaiton with the RNA-splicing apparatus as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>the normal splice junction, is not recognized in the immunoprecipitaiton with the RNA-splicing apparatus as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>the normal splice junction, was not recognized in the immunoprecipitaiton with the RNA-splicing apparatus as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>the normal splice junction, will not be recognized in the immunoprecipitaiton with the RNA-splicing apparatus as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
